In fact, treatment with guadecitabine or DAC vs. AZA induced the expression of NY-ESO-1 in 100% (10/10), 100% (10/10) vs. 80% (8/10) (Figure 2D), of MAGE-A3 in 100% (9/9), 100% (9/9) vs. 77.8% (7/9) (Figure 2E) and of MAGE-A1 in 77.8% (7/9), 88.9% (8/9) vs. 77.8% (7/9) (Figure 2F) CTA-negative hematologic cancer cell lines, respectively. This evidence concerns the gene MAGEA1 and hematopoietic and lymphoid cell neoplasm.